Carbestop Injection

Introduction

Carbestop Injection 250 mcg/ml is a synthetic prostaglandin analogue used primarily to manage postpartum hemorrhage and induce labor. It is administered by injection and acts on the uterine muscles to promote contraction and control bleeding.

Uses

Carbestop Injection 250 mcg/ml is used for:

Management of postpartum hemorrhage due to uterine atony
Induction of labor in cases of missed or incomplete abortion
Treatment of severe bleeding during the third trimester of pregnancy

It is particularly effective when used in situations where other methods have failed.

Brand Name	Carbestop
Type	Injection
Weight	250 mcg/ml
Generic	Carboprost Tromethamine
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Carbestop Injection 250 mcg/ml acts as a potent uterotonic agent. It mimics the action of prostaglandin F2α, stimulating the uterine muscles to contract, which helps in reducing postpartum bleeding by improving uterine tone and reducing blood loss.

How Long Does It Take to Work?

Carbestop Injection 250 mcg/ml typically starts to work within 15 to 30 minutes after injection. The onset of action can vary depending on the patient's condition and the route of administration.

Absorption

When administered intramuscularly, Carbestop Injection 250 mcg/ml is rapidly absorbed into the bloodstream, leading to quick onset of its therapeutic effects. The systemic absorption ensures effective delivery to the target tissues.

Route of Elimination

Carbestop Injection 250 mcg/ml is primarily metabolized in the liver. It is then excreted through the urine. The drug is broken down into inactive metabolites, which are subsequently eliminated from the body.

Dosage

Abortion: An initial dose of 1 ml of Carbestop (containing the equivalent of 250 mcg of Carboprost) is to be administered intramuscularly. Subsequent doses of 250 mcg should be administered at 1½ to 3½ hour intervals depending on uterine response. An optional test dose of 100 mcg (0.4 ml) may be administered initially. The dose may be increased to 500 micrograms (2 ml) if uterine contractility is judged to be inadequate after several doses of 250 mcg (1 ml). The total dose administered of Carbestop should not exceed 12 mg and continuous administration of the drug for more than 2 days is not recommended.

For Refractory Postpartum Uterine Bleeding: An initial dose of 250 mcg of Carbestop (1 ml) is to be given deep, intramuscularly (IM). If needed the dose of 1 ml may be repeated between 15 to 90 minutes. The total dose of Carbestop should not exceed 2 mg (8 doses).

The standard dosage for Carbestop Injection 250 mcg/ml is:

For postpartum hemorrhage: 250 micrograms (mcg) intramuscularly every 15 to 90 minutes, as needed, up to a maximum of 2 milligrams (mg)
For labor induction: Doses and administration may vary based on clinical circumstances and are tailored to the specific needs of the patient

Dosage adjustments may be necessary based on the patient's response and medical condition.

Administration

Carbestop Injection 250 mcg/ml is administered via intramuscular injection, typically in the upper thigh or buttocks. Proper aseptic technique should be used to avoid infection.

Side Effects

Common side effects include:

Nausea and vomiting
Diarrhea
Fever
Headache
Chills and shivering

Serious side effects may include severe uterine contractions, allergic reactions, and cardiovascular disturbances.

Toxicity

Toxicity symptoms may include excessive uterine contractions leading to uterine rupture, severe gastrointestinal disturbances, or cardiovascular issues. In case of suspected overdose or severe reaction, medical attention should be sought immediately.

Precautions

Precautions include:

Monitoring for excessive uterine contractions and fetal distress during administration
Ensuring that the patient does not have contraindications to prostaglandin therapy
Monitoring for signs of gastrointestinal bleeding or other systemic reactions

Close monitoring is essential to ensure safety and efficacy.

Interaction

Interactions with other medications may include:

Other uterotonics: Use with caution to avoid overstimulation of uterine contractions
Anticoagulants: Monitoring is necessary as Carbestop Injection 250 mcg/ml may increase bleeding risk

Patients should inform their healthcare provider of all medications they are taking.

Disease Interaction

Disease interactions may include:

Cardiovascular conditions: Carbestop Injection 250 mcg/ml can affect blood pressure and heart rate
Renal or hepatic impairment: Dosage adjustments may be necessary due to altered metabolism and excretion

Special consideration should be given to patients with these conditions.

Drug Interaction

Drug interactions may include:

Antihypertensives: May interact with Carbestop Injection 250 mcg/ml's effects on blood pressure
Anti-inflammatory drugs: May exacerbate gastrointestinal side effects

Patients should consult their healthcare provider about potential drug interactions.

Food Interactions

No significant food interactions have been reported. However, patients should follow general dietary recommendations to maintain overall health.

Pregnancy Use

Carbestop Injection 250 mcg/ml is used during pregnancy, specifically in the context of labor induction and postpartum hemorrhage management. It should be administered under strict medical supervision due to its potent effects on uterine contractions.

Lactation Use

The effects of Carbestop Injection 250 mcg/ml on breastfeeding are not well-documented. It is advisable to monitor the infant for potential side effects if the drug is administered to a lactating mother.

Acute Overdose

Acute overdose symptoms may include severe uterine contractions, excessive bleeding, or cardiovascular issues. Immediate medical intervention is required, including supportive measures and monitoring of the patient’s condition.

Contraindication

Contraindications include:

Known hypersensitivity to Carbestop Injection 250 mcg/ml or other prostaglandins
Active pelvic inflammatory disease or infection
Severe asthma or other conditions exacerbated by prostaglandins

These conditions may increase the risk of adverse effects and should be evaluated before administration.

Use Direction

Carbestop Injection 250 mcg/ml should be used according to the specific indications and dosing guidelines provided by the healthcare provider. Ensure accurate dosing and monitor the patient closely for any adverse effects.

Storage Conditions

Store Carbestop Injection 250 mcg/ml at room temperature, away from light and moisture. It should be kept out of reach of children and disposed of properly if expired or unused.

Volume of Distribution

The volume of distribution for Carbestop Injection 250 mcg/ml is approximately 0.2 L/kg. This reflects the extent to which the drug disperses into body tissues and fluids.

Half Life

The half-life of Carbestop Injection 250 mcg/ml is approximately 20 minutes. This short half-life contributes to its rapid onset and offset of action.

Clearance

Carbestop Injection 250 mcg/ml is primarily cleared from the body through metabolism in the liver and excretion via the urine. The clearance rate can be affected by liver function and other individual patient factors.

See in details version Carbestop Injection 250 mcg/ml also Carbestop Injection 250 mcg/ml in bangla